Leti-101 Shows Promise in Preclinical Huntington’s Disease Study
ElevateBio has unveiled preclinical data for LETI-101, a CRISPR-based therapy for Huntington’s Disease (HD) being developed by its subsidiary,...
FDA Grants Auron Therapeutics Fast Track Designation for AUTX-703 to Treat AML
Auron Therapeutics received FDA Fast Track designation for AUTX-703, an oral KAT2A/B degrader, for treating relapsed or refractory acute...
Duvakitug Shows Promise in Ulcerative Colitis and Crohn’s Disease
Teva Pharmaceuticals and Sanofi announced positive Phase 2b results for duvakitug, a novel antibody targeting TL1A, in patients with...
Samsung Bioepis Launches Stelara® Biosimilar Pyzchiva® in US
Samsung Bioepis launched PYZCHIVA (ustekinumab-ttwe), a biosimilar to Stelara, in the United States. The drug is approved to treat...
Komen Calls for Urgent Action on Racial Disparities in Breast Cancer
New data reveals that Black women in the U.S. have a significantly higher mortality rate from breast cancer than...
EG 427 Gets €27M in Series B Funding for Clinical Study
EG 427, a biotech company developing targeted genetic medicines for neurological conditions, secured €27 million in Series B funding....
Phoenix Molecular Designs Doses First Patient with PMD-026 in Dauntless-1 Trial
Phoenix Molecular Designs (PhoenixMD) has initiated Phase 2 clinical trials (Dauntless-1) for PMD-026, a first-in-class pan-RSK inhibitor, in combination...
Saudi Arabia Clinical Trials Market Report: Insights & Analysis
Saudi Arabia is rapidly becoming a hub for clinical trials in the Middle East, with over 400 active studies...
Neurona’s Epic Nrtx-1001 Cell Therapy Epilepsy Study
Neurona Therapeutics, a clinical-stage biotherapeutics company, is initiating its Phase 3 EPIC clinical trial for NRTX-1001, a regenerative cell...
Shattuck Labs Announces Positive SL-325 Data at ECCO 2025
Shattuck Labs announced positive preclinical data from a toxicology study of SL-325, a high-affinity DR3 blocking antibody being developed...